期刊
HEPATOLOGY RESEARCH
卷 45, 期 13, 页码 1363-1367出版社
WILEY
DOI: 10.1111/hepr.12513
关键词
antiviral prophylaxis; CC chemokine receptor type 4; hepatitis B virus; mogamulizumab; reactivation
资金
- Ministry of Health, Labor and Welfare of Japan [H24-kanen-004]
- Ministry of Education, Culture, Sports Science and Technology of Japan [24591428]
- National Cancer Center Research and Development Fund [26-A-4]
- Grants-in-Aid for Scientific Research [24591434, 24591428, 221S0001] Funding Source: KAKEN
We report an adult T-cell leukemia-lymphoma (ATL) patient suffering from fatal reactivation of hepatitis B virus (HBV) infection after treatment with the anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, mogamulizumab. HBV reactivation occurred without liver damage in this hepatitis B surface antigen (HBsAg) negative patient, who was seropositive for antibodies against the viral core and surface antigens at baseline, after two cycles of CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisolone) followed by six cycles of THP-COP regimen (cyclophosphamide, pirarubicin, vincristine and prednisolone). Unexpectedly, mogamulizumab monotherapy for relapsed CCR4 positive ATL induced sudden and fatal liver failure due to HBV reactivation, despite antiviral prophylaxis with entecavir. This clinical course may not only offer important suggestions to prevent critical HBV reactivation in HBsAg positive cancer patients who receive immune-enhancing drugs such as anti-CCR4 antibody, but also provide a clue to understanding the pathogenesis of HBV reactivation following systemic chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据